Enhancing peripheral Aβ clearance may be a potential therapy for NAFLD-induced cognitive dysfunction and hepatic LRP-1 may be a key target for intervention. The gene discussed is LRP1; the disease is metabolic dysfunction-associated steatotic liver disease.